Fig. 10
Rescue of decorin and NOV restores breast cancer cell proliferation to levels seen with the addition of EO-conditioned media. MDA-MB-231 or MCF-7 cells were plated at 1 × 105 cells/cm2 in 35 × 10 mm dishes, then treated with either corresponding EO variant CM (e.g., MDA-MB-231 cells treated with EO-231 CM), corresponding EO variant CM in the presence of either anti-NOV or decorin protein or corresponding EO variant CM in the presence of either either anti-NOV PLUS recombinant NOV protein or decorin recombinant protein PLUS decorin antibody. Three individual replicates per time point per condition were plated. On days 1, 2, 3, 4, and 5, cancer cells were detached and counted using a hemocytometer. a MDA-MB-231 cells treated with either EO-231 CM, EO-231 CM plus anti-NOV, or EO-231 CM plus anti-NOV plus NOV protein. b MCF-7 cells treated with either EO-MCF7 CM, EO-MCF7 CM plus anti-NOV, or EO-MCF7 CM plus anti-NOV plus NOV protein. c MDA-MB-231 cells treated with either EO-231 CM, EO-231 CM plus decorin protein, or EO-231 CM plus decorin protein plus anti-decorin. d MCF-7 cells treated with either EO-MCF7 CM, EO-MCF7 CM plus decorin protein, or EO-MCF7 CM plus decorin protein plus anti-decorin. *P < 0.05, **P < 0.005, ***P < 0.001 EO CM plus anti-NOV or decorin vs. EO CM plus either anti-NOV plus NOV protein or decorin protein plus anti-decorin treatment. N = 3 biological replicates per condition, per time point